Durvalumab: A Review in Extensive-Stage SCLC

Area of Science:

• Oncology
• Immunotherapy
• Pharmacology

Background:

• Extensive-stage small cell lung cancer (ES-SCLC) has limited first-line treatment options.
• Programmed cell death-ligand 1 (PD-L1) is a target for cancer immunotherapy.
• Durvalumab is a monoclonal antibody targeting PD-L1.

Purpose of the Study:

• To evaluate the efficacy and safety of durvalumab in combination with chemotherapy for first-line treatment of ES-SCLC.
• To compare durvalumab plus chemotherapy versus chemotherapy alone in the CASPIAN trial.

Main Methods:

• Phase III randomized controlled trial (CASPIAN trial).
• Patients received durvalumab with etoposide and either carboplatin or cisplatin, followed by maintenance durvalumab, or chemotherapy alone.
• Assessed overall survival, progression-free survival, and objective response rates.

Main Results:

• Durvalumab combination therapy demonstrated significantly longer overall survival compared to chemotherapy alone.
• A favorable hazard ratio for progression-free survival was observed with durvalumab plus chemotherapy.
• Higher objective response rates were achieved in the durvalumab combination arm.

Conclusions:

• Durvalumab in combination with etoposide and platinum-based chemotherapy is an effective first-line treatment for ES-SCLC.
• The combination therapy shows a manageable tolerability profile.
• Durvalumab plus chemotherapy is a valuable treatment option and an accepted standard of care for ES-SCLC.